Roche stock falls after breast cancer combo therapy fails in trial
Source: SeekingAlpha
2026-03-09 06:21:00 ET
More on Roche Holding, Pfizer
- Pfizer: Obesity Hype And Vaccine Policy Shocks
- Pfizer's Portfolio Renewal In Progress - High Yields For The Patient
- Pfizer's Quiet Cash Comeback
- Roche continues to expect tariff impact on diagnostics despite U.S. deal
- FDA vaccine chief to leave the agency again
Read the full article on Seeking Alpha
For further details see:
Roche stock falls after breast cancer combo therapy fails in trial
Roche Holding Ltd ADR
NASDAQ: RHHBY
RHHBY Trading
2.52% G/L:
$54.26 Last:
721,223 Volume:
$54.18 Open:
RHHBY Latest News
March 09, 2026 02:10:00 am
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
RHHBY Stock Data
$361,973,933,704
6,306,832,002
N/A
43
N/A
Pharmaceuticals
Healthcare
CH
Basel Switzerland
